Modeling and biological evaluation of pegmolesatide, a novel and potent erythropoiesis-stimulating agent.
J Asian Nat Prod Res
; : 1-9, 2024 Jun 11.
Article
em En
| MEDLINE
| ID: mdl-38860546
ABSTRACT
Pegmolesatide, a synthetic, polyethylene-glycolylated, peptide-based erythropoiesis-stimulating agent (ESA), has been recently approved in China. Pegmolesatide is derived from the structure of endogenous erythropoietin (EPO), a natural product in mammals. This study compared the in vitro effects and selectivity of pegmolesatide to those of recombinant EPO and carbamylated EPO (CEPO) through computer-aided analyses and biological tests. The findings indicate that pegmolesatide exhibited the same stimulating effect on erythropoiesis as EPO with fewer side effects than EPO and CEPO.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
J Asian Nat Prod Res
Ano de publicação:
2024
Tipo de documento:
Article